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INTRODUCTION 
Drug delivery systems, like pegylated drug delivery with 
modified albumin and catalase, and nanoparticles aided 
camptothecin, hold much promise for tumor patients. Both 
forms attempt a more targeted and efficient delivery and 
circulation time of the drug and this assures better results1-9.  
The success of a pegylated drug delivery system with 
modified albumin and catalase has been researched, and it 
was identified that. PEG chains modified with various 
molecular weights made them efficient in targeted therapy 
and diagnosis10-17. The below is the PEG PCL polymersomes 
and their actual effect on glioblastomas in-vitro and in-vivo 
(Figure 1)18. 
 
 
 
Figure 1: PEG-PCL polymersomes in vitro and in vivo actions-The mapping of relative tumor size against days after degradable 
polymersome injection  
 
Pegylation is a procedure where hydrophilic polymer 
polyethylene glycol PEF is attached to a therapeutic module 
to deliver protein, peptides and other small molecules. In the 
history of PEG delivery, it has been identified that it 
enhances the circulation time of molecule or drugs in vivo 
given the drugs a more enhanced time to localize action. The 
possibilities, available in pegylation, present much potential 
for its use. For instance, the most frequently applied PEG is 
dual hydroxyl groups-the HO-PEG-OH or the monomethoxy 
PEG (mPEG) which is a single hydroxyl group19-24. While 
these are standard forms, the chemistry of pegylation means 
that active groups can be used to modify PEG, and this offers 
for more diverse uses. Research works specifically showed 
how pegylated gold nanorods that trigger the drug release 
improve the efficacy of the drug in mouse with human 
glioblastoma. Cancer cell apoptosis was enhanced. 
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Additionally, the ability of the pegylated liposomes to entrap 
anti-cancer drugs such as Doxorubicin for delivering 
targeted high payload to the tumor and the improved 
stability of the drug are reasons why modified PEG delivery 
systems warrant more research in the context of cancer. The 
nanoparticle-loaded active drug has the potential for target 
delivery of therapeutic agents into tumor cells18,25-30. 
Nanoparticles have the characteristics of enhanced 
permeability and retention, and this allows for the medicine 
to remain in the bloodstream for a much longer time. Drug 
retention in the bloodstream is reported, and this enables 
better-continued action. It was highlighted that the use of 
covalent camptothecin conjugates for nanomedical drug 
delivery also could carry similar benefits. All these studies 
aim to present an enhanced drug delivery system, identical 
to the pegylated drug delivery and the camptothecin 
conjugates in nanomedical drug delivery. 
The review thus presented two critical methods used for 
enhancing therapeutic action on tumors through an 
improved drug delivery system. The improvement in the 
delivery method holds much promise for patients with 
tumors as it helps retain the drug in circulation for more 
extended periods and this is a more effective action31-36. 
More research in this area could reveal ways of 
combinatorial therapies that can be carried out with this 
form of drug delivery.  
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